The rise of combination therapy is anticipated to open up the new avenue for Skin Cancer Drugs Market

 

Skin Cancer Drugs Market

Market Overview:

Skin cancer drugs are used to treat various types of skin cancers including melanoma, basal cell carcinoma (BCC), and squamous cell carcinoma (SCC). The common skin cancer drugs available in the market are chemotherapy drugs, immunotherapy drugs, targeted therapy drugs, and others. Chemotherapy includes drugs like carboplatin and paclitaxel that work by stopping or slowing the growth of cancer cells. Immunotherapy includes drugs like interferons and interleukin-2 that stimulate the body's immune system to fight cancer cells. Targeted therapy includes drugs like vemurafenib and dabrafenib that target specific cancer-causing genes or proteins.

Market Dynamics:
The skin cancer drugs market is primarily driven by the increasing incidence of skin cancer worldwide. For instance, according to the American Cancer Society, over 5.4 million new cases of basal cell and squamous cell skin cancers are diagnosed annually in the U.S. Another key driver is the approval and launch of novel drugs for the treatment of skin cancers. For example, in 2020, the FDA approved endevectin (Braftovi) in combination with binimetinib (Mektovi), for the treatment of BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma. Furthermore, the rising accessibility of advanced diagnostic techniques for early detection of skin cancers also contributes to the market growth. However, the high cost of targeted therapies for skin cancer treatment limits the growth of this market.
Segment Analysis
The global skin cancer drugs market is dominated by basal cell carcinoma segment accounting for over 40% of market share in 2023. Basal cell carcinoma is the most common type of skin cancer worldwide which occurs in the basal cells of the epidermis. Due to higher recurrence rate, availability of latest treatment options and increasing public health awareness about skin cancer treatment, the basal cell carcinoma segment is expected to remain the dominating sub-segment during the forecast period.

PEST Analysis
Political: Stringent regulations regarding drug approval and increasing awareness programs by governments and NGOs in major countries are helping the market growth.
Economic: Growing per capita income in developing countries and rising health insurance coverage are positively impacting the market.
Social: Changing lifestyles, exposure to UV radiation due to outdoor activities and unawareness about skin cancer risks is increasing prevalence of disease and driving the demand.
Technological: Advancements in targeted therapies and combination treatments are helping achieve higher cure rates. Ongoing research in immunotherapies is also anticipated to boost the market.

Key Takeaways
The global Skin Cancer Drugs Market Demand is expected to witness high growth, exhibiting a CAGR of 11% over the forecast period 2023 to 2030, due to increasing prevalence of non-melanoma skin cancer worldwide. The market size is estimated to reach US$ 15 Bn by 2030.

The United States holds the largest share of over 40% of global skin cancer drugs market in 2023 due to high risk of skin cancer associated with lifestyle patterns in the country. Europe is the second largest market for skin cancer drugs driven by high disease incidence. Asia Pacific is expected to be the fastest growing market during the forecast period attributed to large patient pool and rising healthcare expenditure.

Key players operating in the skin cancer drugs market are Novartis, Merck, Roche, Amgen, Pfizer, Sun Pharma, Bristol-Myers Squibb, AstraZeneca, Johnson & Johnson, Valeant, Daiichi Sankyo, Takeda, LEO Pharma, Mylan, Sanofi, Regeneron, Eli Lilly, Bayer, Gilead Sciences, and Astellas Pharma. Major players are focusing on development of advanced targeted therapies and combination drug treatments for better disease management.

For more details on the report, Read-

https://www.pressreleasebulletin.com/skin-cancer-drugs-market-demand-share-analysis/

Comments

Post a Comment

Popular posts from this blog

Precast Concrete Market Is Estimated To Witness High Growth Owing To Increasing Demand for Sustainable Construction Practices

Image
Precast Concrete Market Market Overview: The Precast Concrete Market is witnessing significant growth due to the increasing demand for sustainable construction practices. Precast concrete products are prefabricated in controlled factory conditions, offering several advantages such as improved quality control, reduced construction time, and increased durability. These products are widely used in residential, commercial, and infrastructure projects due to their ability to enhance construction efficiency and productivity. With the growing need for energy-efficient and environmentally friendly buildings, the demand for precast concrete products is expected to rise. Market Key Trends: One key trend in the Precast Concrete Market is the adoption of advanced technology in manufacturing processes. The use of computer-aided design (CAD) and building information modeling (BIM) is enabling manufacturers to produce complex and customized precast concrete products with high precision. Additional
Read more

Relapsed Or Refractory Diffuse Large B Cell Lymphoma Market Growth driven by increased adoption of targeted therapies

Image
Relapsed Or Refractory Diffuse Large B Cell Lymphoma Market Market Overview: Relapsed Or Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) is an aggressive fast-growing type of non-Hodgkin's lymphoma (NHL) cancer that generally affects immune system cells called B cells. DLBCL can occur at any age but is most common in older adults. Novel targeted therapies like chimeric antigen receptor (CAR) T-cell therapies, bispecific antibodies and antibody-drug conjugates are revolutionizing the treatment of R/R DLBCL. These advanced therapies are offering new hope to patients by increasing survival rates. Market key trends: One of the key trends in the R/R DLBCL market is the increasing adoption of CAR T-cell therapies. CAR T-cell therapy is an innovative new approach to treating R/R DLBCL through the use of genetically engineered T-cells. Drugs like Kymriah and Yescarta have proven highly effective in treating certain patients with relapsed or refractory forms of large B-cell lymphoma.
Read more

The global Biopharmaceuticals Market connected with therapeutic biologics

Image
Biopharmaceuticals Market Market Overview: The biopharmaceuticals market comprises medicines produced using biotechnology methods like genetic engineering and includes vaccines, blood components, recombinant therapeutic proteins/antibodies, and monoclonal antibodies. Biopharmaceuticals are often used for treating serious medical conditions like cancer, autoimmune diseases, and other chronic disorders. These drugs provide targeted treatment options and have lesser side effects than traditional small-molecule drugs. The market is witnessing high demand due to increasing prevalence of chronic diseases and growing geriatric population globally. Market key trends: One of the key trends gaining traction in The Biopharmaceuticals Market Demand is the increasing adoption of biosimilars. Biosimilars are quasi-generic versions of original biologics and provide more affordable treatment options when the patents of biologics expire. Regulatory agencies in various regions are also approving bios
Read more